Iatrogenic Neuropathology of Systemic Therapies

Matthew Torre; Mel B Feany

doi:10.1016/j.path.2020.01.004

Iatrogenic Neuropathology of Systemic Therapies

Surg Pathol Clin. 2020 Jun;13(2):331-342. doi: 10.1016/j.path.2020.01.004. Epub 2020 Apr 7.

Authors

Matthew Torre¹, Mel B Feany²

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
² Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: mel_feany@hms.harvard.edu.

PMID: 32389270
DOI: 10.1016/j.path.2020.01.004

Abstract

Administration of systemic antineoplastic agents can result in adverse neurologic events. We describe the clinicopathologic features and putative mechanisms underlying iatrogenic neuropathology of the central nervous system secondary to chimeric antigen receptor (CAR) T-cell therapy and conventional chemotherapy.

Keywords: CAR T cell; Chemotherapy-related cognitive impairment; Iatrogenic; Immune effector cell-associated neurotoxicity syndrome (ICANS); Neuropathology; Neurotoxicity.

Publication types

Review

MeSH terms

Antineoplastic Agents / adverse effects*
Central Nervous System Diseases / chemically induced
Central Nervous System Diseases / etiology*
Central Nervous System Diseases / pathology
Humans
Iatrogenic Disease*
Immunotherapy, Adoptive / adverse effects*

Substances

Antineoplastic Agents